As Congress begins deliberations on Fiscal Year 2027 (FY27) appropriations, continued investment in the National Institutes of Health (NIH) remains essential to sustaining progress in biomedical research and innovation. The Society for Immunotherapy of Cancer (SITC) is proud to join a stakeholder letter led by the American Society of Gene & Cell Therapy (ASGCT) advocating for strong federal support for NIH funding in FY27. View the letter in its entirety
here.
The letter calls on lawmakers to provide at least $51.303 billion in funding for NIH and to ensure that appropriated funds are distributed in a timely manner once enacted. Stable and predictable federal investment is critical to maintaining momentum in scientific discovery, supporting groundbreaking research, and accelerating the development of new therapies for patients.
NIH funding plays a foundational role in advancing biomedical innovation, including emerging approaches in cell and gene therapy that have the potential to transform patient outcomes. Continued support for NIH enables researchers, clinicians, and institutions to pursue cutting-edge science, foster collaboration, and translate discoveries into meaningful treatments for patients.
By signing onto this stakeholder letter, SITC remains committed to advocating for policies that accelerate innovation and bring life-saving treatments to patients.